A 37-year-old man with a 6-year ocular history of bilateral chronic CSC with multiple recurrences presented with a 3-month history of central scotoma, reduced vision and metamorphopsia in his right eye. We report the favorable anatomic and functional outcome of photodynamic therapy with verteporfin in a case of chronic central serous chorioretinopathy complicated with choroidal neovascularization (CNV). This 37-year-old Chinese male with bilateral chronic central serous chorioretinopathy presented with central scotoma, reduced vision and metamorphopsia in his right eye. Fluorescein angiography (FA) disclosed macular hemorrhage, exudate and subfoveal classic CNV. Photodynamic therapy (PDT) with verteporfin was applied to the CNV according to standard protocol with 2.2-mm spot size. Best-corrected visual acuity (BCVA) improved from 6/20 to 6/10 1 month after PDT. BCVA recovered to 6/7.5 without leakage on FA 3 months after PDT. Neither recurrent CNV lesion nor new hemorrhage was noted over 12 months of follow-up. Short-term results suggest that PDT with verteporfin for CNV secondary to central serous chorioretinopathy is a safe and effective treatment modality. [J Chin Med Assoc 2009;72(9):501-505] 
Introduction
Central serous chorioretinopathy (CSC) is a disease that predominantly affects middle-aged adults. Males are 5-10 times more likely to develop CSC than females. CSC commonly involves the sensory retina and retinal pigment epithelium (RPE), and presents as either ink blot or smokestack type of hyperfluorescence on fluorescein angiography (FA). It may be associated with emotional stress, a type A achievement-oriented personality, systemic steroid use and pregnancy. 1 The disease is usually benign and self-limited, with good visual recovery. However, approximately 5% of CSC cases may have a poor visual outcome due to the disease being chronic. Persistent subretinal fluid, central RPE atrophy, atrophic RPE tracts inferior to the macula, cystoid macular edema, severe RPE degeneration, and choroidal neovascularization (CNV) are reported to be correlated with a poor visual outcome of chronic CSC. 1, 2 CNV secondary to CSC is a rare but potentially sight-threatening complication. Photodynamic therapy (PDT) with verteporfin has been proven to be beneficial for classic subfoveal CNV secondary to age-related macular degeneration (AMD) or pathologic myopia. CNV secondary to CSC may be potentially ameliorated by PDT because it usually presents as classic membrane on FA. Until recently, there were few studies concerning the outcome of PDT in patients with CSC complicated with CNV in Asia. 3 Herein, we report the successful treatment and good visual outcome of PDT in such a case.
He had no history of systemic diseases. Best-corrected visual acuity (BCVA) was 6/20 in the right eye and 6/6.7 in the left eye. There was macular hemorrhage with exudation and pigment clumping within the posterior pole in the right eye ( Figure 1A) , whereas an old glial scar was evident in the posterior pole in the left eye ( Figure 1D ). Intravenous FA disclosed subfoveal CNV in the right eye with early hyperfluorescence and late leakage, and multifocal areas of nodular hyperfluorescence due to depigmentation of the RPE ( Figures 1B and 1C) . FA in the left eye showed a gliotic scar with early hyperfluorescence and late staining without leakage ( Figures 1E and 1F ). Indocyanine green angiography (ICGA) revealed subfoveal CNV with hyperfluorescence dye leakage in the right eye ( and no exudation, with prominent fovea light reflex in the right eye ( Figure 3C ). There was only staining with absence of leakage on FA ( Figure 3D ). The left eye was stationary throughout the whole course during follow-up.
Discussion
Central serous chorioretinopathy has a heterogeneous course. Most cases resolve spontaneously without any treatment. However, a small but meaningful subset of patients with CSC may develop chronic disease. Patients with chronic CSC may have a poor visual prognosis, especially those with clinical features such as persistent pigment epithelial detachment (PED) with subretinal fluid, multiple recurrences with foveal involvement, and subfoveal CNV. 1 These CNV commonly arise in patients with a history of longstanding CSC, persistent or recurrent attacks, chronic diffuse epitheliopathy, or an older age at presentation. Our patient belongs to this group of patients. The exact pathogenesis for the development of CNV in patients with CSC is unclear. We hypothesize that chronic decompensation or disruption at the RPE-Bruch membrane complex together with ischemic changes at the choriocapillaries may be important factors in CNV.
CSC develops primarily as a result of choroidal vascular hyperpermeability evidenced by ICGA study. PDT is a selective therapeutic modality that has been shown to occlude the hyperproliferative vessels and normalize the calibers of dilated and congested choroidal vasculature while leaving normal choroidal tissue unharmed, as compared to conventional laser therapy. 3 Recently, PDT with verteporfin has been used in the treatment of chronic CSC, with beneficial visual outcomes in the majority of patients in Western reports. [3] [4] [5] [6] [7] In the literature, there are few reports concerning PDT treatment of CSC in Asia. 3, 5 We found a favorable anatomic and functional outcome at the 1-and 3-month follow-ups in a Chinese patient who remained stable without recurrence of CNV 12 months after PDT treatment.
ICGA is a very useful diagnostic tool with the advantage of being able to establish the correct diagnosis of CSC compared with FA. Characteristic ICGA findings include hyperpermeability of choroidal vessels with associated active RPE leaks, and multiple presumed occult serous RPE detachments in both eyes. 8, 9 Differentiating CSC from other retinal diseases is the absence of polypoidal lesions and hot spots that are seen in polypoid choroidal vasculopathy and AMD. 5, 10, 11 PDT treatment in patients with CSC associated with CNV might be successful because PDT also affects the longstanding non-neovascular component of CSC. 6 ICGA-guided PDT with verteporfin seems to aid in the resolution of exudative detachment in patients with chronic CSC. 9 PDT treatment is associated with a rapid reduction in subretinal fluid and improvement in visual acuity. In our patient, PDT was able to treat both the disease itself and CNV. Furthermore, PDT has the advantage of being less invasive than submacular surgery. 2 Due to long-term safety concerns and the possible risk of choroidal damage after PDT, recent reports have focused on reduced-dose verteporfin PDT for chronic CSC instead of the traditional standard protocol.
12,13 RPE tear following PDT in the treatment of CNV associated with AMD has also been reported to be a potential risk of PDT. 14 In conclusion, PDT with verteporfin is an effective and promising treatment with good visual outcome in patients with CSC associated with CNV. Patient selection and early intervention remain vital in the treatment of this group of patients. Further prospective study would be beneficial to demonstrate the longterm safety and efficacy of PDT in treating CNV secondary to CSC in the Chinese population.
